MWN-AI** Summary
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a clinical-stage regenerative medicine company based in Melville, New York, has announced that it will release its financial results for the second quarter of 2025 after the market closes on August 12, 2025. The company will follow up the announcement with a conference call at 4:30 p.m. ET, where management will discuss the financial results and provide a business update. Interested parties can join the conference call by dialing 1-888-506-0062 domestically or 1-973-528-0011 internationally, using access code 436077. The call will also be streamed live and archived on the company’s website under the Investors section.
BioRestorative specializes in developing stem cell-based therapies, with its core clinical programs focusing on treating disc/spine diseases and metabolic disorders. The company's lead product, BRTX-100, utilizes autologous cultured mesenchymal stem cells harvested from a patient’s bone marrow. This product is designed for the non-surgical treatment of lumbosacral disc disorders and recently entered a Phase 2 clinical trial aimed at chronic lower back pain from degenerative disc disease.
Additionally, BioRestorative is exploring its ThermoStem® metabolic program, which leverages brown adipose-derived stem cells to combat obesity and metabolic disorders through the generation of brown adipose tissue. Their BioCosmeceutical platform includes a proprietary serum aimed at reducing cosmetic signs of aging, indicating a broadening interest in aesthetic applications.
Investors should be mindful that the company’s forward-looking statements involve various risks that could affect future performance, emphasizing the importance of evaluating these uncertainties in connection with their financial outlook.
MWN-AI** Analysis
As BioRestorative Therapies, Inc. (NASDAQ: BRTX) prepares to release its second-quarter financial results on August 12, 2025, investors should reflect on the company's current standings and future potential within the regenerative medicine sector. BioRestorative is notable for its innovative therapeutic protocols that leverage adult stem cells, focusing primarily on the treatment of painful disc/spine diseases and metabolic disorders.
The upcoming conference call presents a pivotal moment for investors. If past performance, notably in clinical trials, confirms the efficacy and safety of its lead product BRTX-100, investor sentiment may shift positively, enhancing the stock's attractiveness. The Phase 2 trial of BRTX-100 for chronic lower back pain, coupled with FDA IND clearance for chronic cervical discogenic pain, positions the company at the forefront of emerging treatments that could redefine non-surgical pain management. Investors should closely monitor trial results, as positive data could catalyze a substantial price appreciation.
Moreover, BioRestorative's initiatives in the metabolic health arena, particularly the ThermoStem program targeting obesity, could yield significant returns as obesity rates rise globally. Should their findings continue to support the hypothesis that increased brown adipose tissue (BAT) can regulate metabolic function, the company may tap into a lucrative market, drawing interest from both strategic partners and investors.
Lastly, the BioCosmeceutical line, focused on aesthetic applications of stem cell technology, opens additional revenue streams. As consumer interest in effective, non-invasive beauty solutions grows, this segment could provide a competitive advantage and diversify risk.
In summary, as Q2 results approach, stakeholders should evaluate BioRestorative’s clinical progress, potential market expansions, and investor communications for insights that could inform strategic investment decisions. The upcoming announcement and follow-up discussion could be catalysts for volatility, presenting both opportunities and risks for market participants.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
Second Quarter 2025 Results Conference Call Details:
| Date: | Tuesday, August 12, 2025 |
| Time: | 4:30 p.m. ET |
| Domestic: | 1-888-506-0062 |
| International: | 1-973-528-0011 |
| Access Code: | 436077 |
The call will also be broadcast live and archived on the Company's website under News & Events/IR Calendar in the Investors section.
About BioRestorative Therapies, Inc.
BioRestorative ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem ® ): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ**
How do the upcoming second quarter financial results for BioRestorative Therapies Inc (BRTXD) align with market expectations and what metrics are investors particularly interested in monitoring during the August 12th conference call?
Can BioRestorative Therapies Inc (BRTXD) provide updates on the progress of the Phase 2 clinical trial for BRTX-100 and how it could potentially impact financial performance in the near term?
What are the key milestones that BioRestorative Therapies Inc (BRTXD) anticipates achieving in its metabolic program targeting obesity, and how might these developments affect investor confidence?
How does BioRestorative Therapies Inc (BRTXD) plan to expand its BioCosmeceuticals platform, and what financial implications might arise from potential FDA approvals for these emerging products?
**MWN-AI FAQ is based on asking OpenAI questions about BioRestorative Therapies Inc (OTC: BRTXD).
NASDAQ: BRTXD
BRTXD Trading
3.81% G/L:
$13.50 Last:
17,311 Volume:
$14.94 Open:
